Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Generics Market Outlook 2015 |
Oct 2010 | £4,805 | 100% |
| GSK's Cervarix A Future Blockbuster of 2007 |
Mar 2007 | £1,999 | 98% |
| Rimonabant: The first of the Cannabinoid blockbusters | Jun 2007 | £1,499 | 96% |
| AMD Market Outlook to 2012 | Mar 2007 | £1,299 | 95% |
| Wyeth: PharmaVitae Profile | Mar 2009 | £3,605 | 94% |
| Pharmaceutical Innovation: Driver of Long-Term Value | Dec 2010 | £305 | 93% |
| Pre-Launch Planning: Priming Your Pharmaceutical Brand for Profit and Success 2011 |
Jun 2011 | £997 | 93% |
| Sanofi-Aventis PharmaVitae Profile |
Nov 2010 | £3,605 | 92% |
| Cancer Drug Blockbusters The prospects and challenges to 2016 for 21 oncology products valued at over US$1 billion |
Nov 2010 | £1,295 | 89% |
| Nycomed A/S: PharmaVitae Profile | Mar 2009 | £3,605 | 88% |
| Indication Expansion Opportunities for successful lifecycle management |
Mar 2007 | £1,210 | 86% |
| Pharmaceutical Company Outlook to 2015 | Dec 2010 | £4,805 | 86% |
| Pharmaceutical Outsourcing Opportunities Post-Launch: Contract Manufacturing and Contract Sales and Marketing 3rd Edition |
Jan 2009 | £2,215 | 86% |
| Trends in Pharmaceutical Portfolio Management Strategies to Maintain Profitability despite Adversity |
Sep 2008 | £2,405 | 85% |
| The Cardiovascular Market Outlook to 2016 Healthcare |
Jun 2011 | £2,425 | 84% |
| UK Generics Market Analysis | Apr 2011 | £505 | 84% |
| Nycomed S.C.A SICAR PharmaVitae Profile |
Jul 2010 | £125 | 83% |
| The Pharmaceutical Industry Key events and trends shaping its current status and future direction |
Mar 2006 | £2,335 | 83% |
| Booming US Generic Drug Market | Mar 2011 | £630 | 83% |
| Direct to Consumer (DTC) Advertising in Pharmaceuticals Current and Future Market Outlook, Regulatory Landscape and Case Studies |
Dec 2009 | £2,215 | 82% |
| Global Smoking Cessation Market Analysis & Forecasts Preparing For The First Blockbuster |
Jul 2007 | £1,499 | 82% |
| Gastrointestinal Disorders Market Intelligence to 2012 | May 2007 | £1,499 | 81% |
| Bristol-Myers Squibb Co. PharmaVitae Profile |
Dec 2010 | £3,605 | 81% |
| Osteoporosis Drugs Technologies and Global Markets |
May 2010 | £3,065 | 80% |
| Novartis AG: PharmaVitae Profile | Jun 2010 | £3,605 | 80% |
| Pharmaceutical Pricing and Reimbursement Strategies for market access across the Us, Europe, Japan and other key geographies |
Nov 2007 | £1,820 | 79% |
| Shire plc: PharmaVitae Profile Company Report |
Jun 2010 | £3,605 | 78% |
| Emerging Opportunities in Controlled-Release Generic Drugs | Aug 2009 | £995 | 78% |
| Amgen Inc.: PharmaVitae Profile Healthcare |
Mar 2009 | £3,605 | 78% |
| Pharma Company Profiles - Chugai Pharmaceutical Co. | Oct 2008 | £255 | 77% |
